Mendelsohn, J. & Baselga, J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer J. Clin. Oncol.21, 2787–2799 (2003). ArticleCASPubMed Google Scholar
Cohen, S. Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. J. Biol. Chem.237, 1555–1562 (1962). CASPubMed Google Scholar
Cohen, S. & Carpenter, G. Human epidermal growth factor: isolation and chemical and biological properties. Proc. Natl Acad. Sci. USA72, 1317–1321 (1975). ArticleCASPubMedPubMed Central Google Scholar
Gregory, H. Isolation and structure of urogastrone and its relationship to epidermal growth factor. Nature257, 325–327 (1975). ArticleCASPubMed Google Scholar
Cohen, S., Carpenter, G. & King, L. Jr. Epidermal growth factor receptor-kinase interactions: co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity. J. Biol. Chem.255, 4834–4842 (1980). CASPubMed Google Scholar
Sporn, M. B. & Todaro, G. J. Autocrine secretion and malignant transformation of cells. N. Engl. J. Med.303, 878–880 (1980). ArticleCASPubMed Google Scholar
Cohen, S., Carpenter, G. & King, L. Jr. Epidermal growth factor-receptor-protein kinase interactions. Prog. Clin. Biol. Res.66, 557–567 (1981). PubMed Google Scholar
Ozanne, B., Richards, C. S., Hendler, F., Burns, D. & Gusterson, B. Over-expression of the EGF receptor is a hallmark of squamous cell carcinomas. J. Pathol.149, 9–14 (1986). ArticleCASPubMed Google Scholar
Umekita, Y., Ohi, Y., Sagara, Y. & Yoshida, H. Co-expression of epidermal growth factor receptor and transforming growth factor-α predicts worse prognosis in breast-cancer patients. Int. J. Cancer89, 484–487 (2000). ArticleCASPubMed Google Scholar
Mendelsohn, J. Blockade of receptors for growth factors: an anticancer therapy: The Fourth Annual Joseph H. Burchenal American Association for Cancer Research Clinical Research Award Lecture. Clin. Cancer Res.6, 747–753 (2000). CASPubMed Google Scholar
Gill, G. N. et al. Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J. Biol. Chem.259, 7755–7760 (1984). CASPubMed Google Scholar
Fan, Z., Masui, H., Atlas, I. & Mendelsohn, J. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res.53, 4322–4328 (1993). CASPubMed Google Scholar
Kawamoto, T. et al. Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc. Natl Acad. Sci. USA80, 1337–1341 (1983). ArticleCASPubMedPubMed Central Google Scholar
Sato, J. D. et al. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol. Biol. Med.1, 511–529 (1983). CASPubMed Google Scholar
Goldstein, N. I., Prewett, M., Zuklys, K., Rockwell, P. & Mendelsohn, J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res.1, 1311–1318 (1995). CASPubMed Google Scholar
Divgi, C. R. et al. Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J. Natl Cancer Inst.83, 97–104 (1991). ArticleCASPubMed Google Scholar
Baselga, J. et al. Comparative pharmacology in phase I and imaging trails utilising anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (MAbs) labeled with 1311 or 111n. Proc. Am. Soc. Clin. Oncol.12, 142 (1993). Google Scholar
Brady, L. W. et al. Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: a phase II trial. Int. J. Radiat. Oncol. Biol. Phys.22, 225–230 (1992). ArticleCASPubMed Google Scholar
Perez-Soler, R. et al. Tumor epidermal growth factor receptor studies in patients with non-small-cell lung cancer or head and neck cancer treated with monoclonal antibody RG 83852. J. Clin. Oncol.12, 730–739 (1994). ArticleCASPubMed Google Scholar
Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med.350, 2129–2139 (2004). ArticleCASPubMed Google Scholar
Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science304, 1497–1500 (2004). ArticleCASPubMed Google Scholar
Pao, W. et al. EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. USA101, 13306–13311 (2004). ArticleCASPubMedPubMed Central Google Scholar
Barker, A. J. et al. Studies leading to the identification of ZD1839 (Iressa™): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg. Med. Chem. Lett.11, 1911–1914 (2001). ArticleCASPubMed Google Scholar
Ward, W. H. et al. Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochem. Pharmacol.48, 659–666 (1994). ArticleCASPubMed Google Scholar
Wakeling, A. E. et al. ZD1839 (Iressa); an orally active inhibitor of epidermal growth factor signalling with potential for cancer therapy. Cancer Res.62, 5749–5754 (2002). CASPubMed Google Scholar
Ciardiello, F. et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res.6, 2053–2063 (2000). CASPubMed Google Scholar
Sirotnak, F. M., Zakowski, M. F., Miller, V. A., Scher, H. I. & Kris, M. G. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res.6, 4885–4892 (2000). CASPubMed Google Scholar
Swaisland, H. et al. Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers. Clin. Pharmacokinet.40, 297–306 (2001). ArticleCASPubMed Google Scholar
Herbst, R. S. et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J. Clin. Oncol.20, 3815–3825 (2002). ArticleCASPubMed Google Scholar
Ranson, M. et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J. Clin. Oncol.20, 2240–2250 (2002). ArticleCASPubMed Google Scholar
Baselga, J. et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J. Clin. Oncol.20, 4292–4302 (2002). ArticleCASPubMed Google Scholar
Nakagawa, K. et al. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumours. Ann. Oncol.14, 922–930 (2003). ArticleCASPubMed Google Scholar
Tolcher, A. W., Takimoto, C. H. & Rowinsky, E. K. The multifunctional, multi-institutional, and sometimes even global phase I study: a better life for phase I evaluations or just 'living large'? J. Clin. Oncol.20, 4276–4278 (2002). ArticlePubMed Google Scholar
Albanell, J. et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J. Clin. Oncol.20, 110–124 (2002). ArticleCASPubMed Google Scholar
Kris, M. G. et al. Objective regressions in non-small cell lung cancer patients treated in phase I trials of oral ZD1839 ('Iressa'), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR). Lung Cancer29 (Suppl. 1), 72 (2000). Article Google Scholar
National Cancer Institute. National Cancer Institute Cancer Therapy Evaluation Program: Common Toxicity Criteria Manual: Common Toxicity Criteria version 2 [online], <http://ctep.cancer.gov/forms/CTCManual_v4_10-4-99.pdf> (1999).
Wolf, M., Swaisland, H. & Averbuch, S. Development of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacy. Clin. Cancer Res.10, 4607–4613 (2004). ArticleCASPubMed Google Scholar
Fukuoka, M. et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J. Clin. Oncol.21, 2237–2246 (2003). ArticleCASPubMed Google Scholar
Kris, M. G. et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. A randomized trial. JAMA290, 2149–2158 (2003). ArticleCASPubMed Google Scholar
Fukuoka, M. et al. Phase II trials of gefitinib ('Iressa', ZD1839): rapid and durable objective responses in patients with advanced non-small-cell lung cancer (IDEAL 1 and IDEAL 2). Lung Cancer41 (Suppl. 2), 247 (2003). Article Google Scholar
Cortes-Funes, H. & Soto Parra, H. Extensive experience of disease control with gefitinib and the role of prognostic markers. Br. J. Cancer89 (Suppl. 2), 3–8 (2003). ArticleCAS Google Scholar
Shepherd, F. A. et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. J. Clin. Oncol.22 (Suppl. 14S), 7022 (2004). Article Google Scholar
Ochs, J., Grous, J. & Warner, K. Final survival and safety results for 21,064 non-small cell lung cancer (NSCLC) patients who received compassionate use gefitinib (IRESSA®) in a United States Expanded Access Program (EAP). J. Clin. Oncol.22 (Suppl. 14S), 7060 (2004). Article Google Scholar
Massarelli, E. et al. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer39, 55–61 (2003). ArticleCASPubMed Google Scholar
van Zandwijk, N. Tolerability of gefitinib in patients receiving treatment in everyday clinical practice. Br. J. Cancer89 (Suppl. 2), 9–14 (2003). ArticleCAS Google Scholar
Tan, A. R. et al. Evaluation of epidermal growth factor receptor signaling in tumor and skin biopsies after treatment with OSI-774 in patients with metastatic breast cancer. Proc. Am. Soc. Clin. Oncol.22, 196 (2003). Google Scholar
Yamamoto, N. et al. A phase I study of erlotinib HCI in Japanese patients with various types of solid tumors. Proc. Am. Soc. Clin. Oncol.22, 225 (2003). Google Scholar
Seto, T. & Yamamoto, N. Interstitial lung diseases (ILD) induced by gefitinib in patients with advanced non-small cell lung cancer (NSCLC): Results of a West Japan Thoracic Oncology Group (WJTOG) epidemiological survey. Proc. Am. Soc. Clin. Oncol.23, 629 (2004). Google Scholar
Koo, L. et al. National differences in reporting 'pneumonia' and 'pneumonia interstitial': An analysis of the WHO adverse events database on 15 drugs in 9 countries for 7 pulmonary conditions. Pharmacoepidemiol. Drug Saf.13, S31–S32 (2004). Google Scholar
Abid, S. H., Malhotra, V. & Perry, M. C. Radiation-induced and chemotherapy-induced pulmonary injury. Curr. Opin. Oncol.13, 242–248 (2001). ArticleCASPubMed Google Scholar
Miller, V. A. et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J. Clin. Oncol.22, 1103–1109 (2004). ArticleCASPubMed Google Scholar
Shepherd, F. A. et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. Proc. Am. Soc. Clin. Oncol. Late-Breaking Abstracts Booklet23, 18 (2004). Google Scholar
Bailey, L. R. et al. Tumor EGFR membrane staining is not clinically relevant for predicting response in patients receiving gefitinib ('Iressa', ZD1839) monotherapy for pretreated advanced non-small–cell lung cancer: IDEAL 1 and 2. Proc. Am. Assoc. Cancer Res.44, 1362 (2003). Google Scholar
Lynch, T., Ranson, M., Herbst, R. & Fukuoka, M. Skin toxicity is not a clinically meaningful prognostic marker for tumor response to gefitinib ('Iressa', ZD1839) in pretreated patients with advanced non-small–cell lung cancer. Clin. Cancer Res.9 (Suppl.), 6086 (2003). Google Scholar
Sordella, R., Bell, D. W., Haber, D. A. & Settleman, J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science305, 1163–1167 (2004). ArticleCASPubMed Google Scholar
Natale, R. B. et al. Quantitative gene expression in non-small cell lung cancer from paraffin-embedded tissue specimens: predicting response to gefitinib, and EGFR kinase inhibitor. Proc. Am. Soc. Clin. Oncol.22, 190 (2003). Google Scholar
Douillard, J. -Y. et al. ZD1839 ('Iressa') provides clinically significant antitumor activity and improves disease-related symptoms in pretreated patients with advanced non-small-cell lung cancer (NSCLC): results of two phase II trials (IDEAL 1 and IDEAL 2). Eur. J. Cancer38 (Suppl. 7), 56–57 (2002). Google Scholar
Giaccone, G. et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial — INTACT 1. J. Clin. Oncol.22, 777–784 (2004). ArticleCASPubMed Google Scholar
Herbst, R. S. et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial — INTACT 2. J. Clin. Oncol.22, 785–794 (2004). ArticleCASPubMed Google Scholar
Gonzalez–Larriba, J. L. et al. ZD1839 ('Iressa') in combination with gemcitabine and cisplatin in chemonaive patients with advanced solid tumours: final results of a phase I trial. Proc. Am. Soc. Clin. Oncol.21, 95a (2002). Google Scholar
Miller, V. A. et al. Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer. J. Clin. Oncol.21, 2094–2100 (2003). ArticleCASPubMed Google Scholar
Gatzemeier, U. et al. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol.23, 617 (2004). Google Scholar
Herbst, R. S. et al. TRIBUTE- A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol.23, 617 (2004). Google Scholar
Baselga, J. Combining the anti-egfr agent gefitinib with chemotherapy in non-small-cell lung cancer: how do we go from INTACT to impact? J. Clin. Oncol.22, 759–761 (2004). ArticleCASPubMed Google Scholar
Albain, K. S. et al. Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from intergroup trial 0100 (SWOG–8814). Proc. Am. Soc. Clin. Oncol.21, 37a (2002). Google Scholar
Solit, D. B. et al. Pulsatile administration of the EGF receptor inhibitor gefitinib ('Iressa', ZD1839) is significantly more effective than continuous dosing sensitizing tumors to Taxol. Clin. Cancer Res.9 (Suppl.), A83 (2003). Google Scholar
Sandler, A. B. et al. Phase I/II trial evaluating the anti-VEGF MAb bevacizumab in combination with erlotinib, a HER1/EGFR-TK inhibitor, for patients with recurrent non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol.23, 127 (2004). Google Scholar
Heymach, J. V. et al. ZD6474, a novel antiangiogenic agent, in combination with docetaxel in patients with NSCLC: Results of the run-in phase of a two-part, randomized phase II study. Proc. Am. Soc. Clin. Oncol.22, 207 (2004). Google Scholar
Niho, S. et al. First-line single agent of gefitinib in patients (pts) with advanced non-small cell lung cancer (NSCLC): A phase II study. Proc. Am. Soc. Clin. Oncol.23, 628 (2004). Google Scholar
Dickson, N. R. et al. Single agent gefitinib in poor performance status patients with previously untreated advanced non-small cell lung cancer: A Minnie Pearl Cancer Research Network phase II trial. Proc. Am. Soc. Clin. Oncol.23, 634 (2004). Google Scholar
Cohen, E. E. W. et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol.21, 1980–1987 (2003). ArticleCASPubMed Google Scholar
Wirth, L. J. et al. Phase I study of gefitinib plus celecoxib in patients with metastatic and/or locally recurrent squamous cell carcinoma of the head and neck (SCCHN). Proc. Am. Soc. Clin. Oncol.23, 496 (2004). Google Scholar
Albain, K. et al. Open-label, phase II, multicenter trial of ZD1839 ('Iressa') in patients with advanced breast cancer. Breast Cancer Res.Treat.76 (Suppl. 1), 33 (2002). Google Scholar
Baselga, J. et al. Phase II and tumor pharmacodynamic study of gefitinib (ZD1839) in patients with advanced breast cancer. Proc. Am. Soc. Clin. Oncol.22, 7 (2003). Google Scholar
Gee, J. M. W. et al. The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology144, 5105–5117 (2003). ArticleCASPubMed Google Scholar
Okubo, S. et al. Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells. Br. J. Cancer90, 236–244 (2004). ArticleCASPubMedPubMed Central Google Scholar
Shou, J. et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J. Natl. Cancer Inst.96, 926–935 (2004). ArticleCASPubMed Google Scholar
McKillop, D. et al. Intratumoral and plasma concentrations of gefitinib ('Iressa') in breast cancer patients: preliminary results from a presurgical investigatory study (BCIRG 103). J. Clin. Oncol.22, (Suppl. 14S) 581 (2004). Article Google Scholar
Fisher, G. A. et al. A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol.23, 249 (2004). Google Scholar
Doi, T. et al. Efficacy, tolerability, and pharmacokinetics of gefitinib ('Iressa', ZD1839) in pretreated patients with metastatic gastric cancer. Proc. Am. Soc. Clin. Oncol.22, 258 (2003). Google Scholar
Prenzel, N., Fischer, O. M., Streit, S., Hart, S. & Ullrich, A. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr. Relat. Cancer8, 11–31 (2001). ArticleCASPubMed Google Scholar
Slichenmyer, W. J. & Fry, D. W. Anticancer therapy targeting the erbB family of receptor tyrosine kinases. Semin. Oncol.28 (Suppl. 16), 67–79 (2001). ArticleCASPubMed Google Scholar
Yarden, Y. & Sliwkowski, M. X. Untangling the ErbB signalling network. Nature Rev. Mol. Cell Biol.2, 127–137 (2001). ArticleCAS Google Scholar
Baselga, J. New technologies in epidermal growth factor receptor-targeted cancer therapy. Signal1, 12–21 (2000). Google Scholar